CSRXP: OVERSIGHT REPORT ADDS TO MOMENTUM IN WASHINGTON TO HOLD BIG PHARMA ACCOUNTABLE
Jul 8, 2021
U.S. House Oversight & Reform Committee Report Shines Light on Branded… Read More
© 2024 CSRXP- All Rights Reserved
Updates
BIG PHARMA WATCH: JULY PRICE HIKES CLIMB TO 52
Jul 7, 2021
Brand Name Drug Companies Stick to Business-as-Usual in Third Major Round of… Read More
CSRxP: Big Pharma Flaunts Disregard for Rx Affordability With Third Major Round of Pandemic Price Hikes
Jul 1, 2021
Pharmaceutical Companies Increase Prices on 32 Brand Name Drugs to Start July… Read More
ICYMI: BIG PHARMA USES INFLUENCE OVER PATIENT GROUPS & ASTROTURF TACTICS TO UNDERMINE RX SOLUTIONS
Jun 30, 2021
New Report Reveals “Hidden Hand” Of Brand Name Drug Industry In case you… Read More
CSRXP APPLAUDS U.S. HOUSE PROBE INTO BIOGEN PRICING OF ADUHELM
Jun 25, 2021
Pallone and Maloney Announce Joint Investigation into Massive Price Tag on… Read More
BIG PHARMA WATCH: HEADLINES SHOW BIOGEN ADHUHELM PRICING HAS REIGNITED URGENCY TO HOLD BIG PHARMA ACCOUNTABLE
Jun 25, 2021
Coverage Highlights Backlash Over Massive Price Tag for Unproven Treatment,… Read More
SECOND OPINION: PFIZER’S PHONY CALL FOR LOWER DRUG COSTS
Jun 22, 2021
CEO Sidesteps Big Pharma’s Pricing Practices; Pushes Proposals That Would… Read More
CSRXP: WYDEN RX PRICING PRINCIPLES ADD TO MOMENTUM IN WASHINGTON TO HOLD BIG PHARMA ACCOUNTABLE
Jun 22, 2021
Lawmakers Must Advance Solutions to Lower Drug Prices Washington,… Read More
WHAT THEY ARE SAYING: BIOGEN’S “SIMPLY UNACCEPTABLE” ADUCANUMAB PRICING HIGHLIGHTS URGENCY FOR RX SOLUTIONS
Jun 14, 2021
Broad-based Opposition to Egregious Launch Price on Drug With Unproven… Read More
CSRXP: FDA APPROVAL AND SUBSEQUENT BIOGEN PRICING OF ADUCANUMAB DEMAND RETROSPECTION, REFORM
Jun 11, 2021
Troubling for Public Health Institution to Depart from Established Norms to… Read More
ICYMI: BIG PHARMA’S FASTER-THAN-INFLATION PRICE HIKES COSTING MEDICARE BILLIONS OF DOLLARS
Jun 7, 2021
AARP Study Finds Brand Name Drug Companies Increased Prices Above Rate of… Read More
SECOND OPINION: DEBUNKING BIG PHARMA’S BOGUS INNOVATION RHETORIC
Jun 7, 2021
For far too long Big Pharma has used the excuse that research and development… Read More